UpdatesPress Release
Accretion Pharma's H1 FY26 saw revenue surge 135.59% to ₹43.74 Cr, EBITDA 62.94% to ₹7.07 Cr, and PAT 92.81% to ₹4.75 Cr.
Accretion Pharmaceuticals LimitedACCPL · Filed with the exchange
Growth fueled by IPO-backed capacity expansion and diversified product offerings.
Expanded global reach with new market approvals for African exports.
No comments yet. Be the first.